Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (NYSE American: MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 30, 2024
Event: Implementation of a 1-for-50 reverse stock split and reduction of authorized shares.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Reverse Stock Split: A 1-for-50 reverse stock split was effected on August 30, 2024, at 5:00 p.m. Eastern Time. Every 50 outstanding shares were converted into 1 share.
- Authorized Share Reduction: The total number of authorized common shares was reduced from 500,000,000 to 250,000,000.
- Security Adjustments: All outstanding options, restricted stock units, and warrants were adjusted proportionally. No fractional shares were issued; fractional entitlements were rounded up to the next whole share.
- CUSIP Change: The CUSIP number for the Common Stock changed to 576810 303.
- Trading Status: Trading was halted on August 27, 2024, due to low share price. Trading is anticipated to resume on a split-adjusted basis on September 3, 2024, subject to NYSE American approval.
Outlook, Risks, and Management Commentary
- Delisting Risk: The Company noted that if the post-split share price does not meet the requirements of Section 1003(f)(v) of the NYSE American Company Guide, the Exchange could suspend trading or move to delist the Common Stock.
- Trading Halt: While not anticipated, the Exchange could maintain the trading halt beyond the anticipated resumption date.
- Approval History: The amendment was approved by stockholders at the Annual Meeting on November 1, 2023, and authorized by the Board of Directors on August 20, 2024.
Investor Verification Checklist
- Confirm the resumption of trading on September 3, 2024, and the new CUSIP number (576810 303).
- Verify that the post-split share price meets NYSE American listing standards to avoid delisting.
- Review the adjustment of personal holdings, options, and warrants to ensure correct conversion ratios were applied.
- Check for any subsequent filings regarding the status of the trading halt or delisting proceedings.